Show simple item record

dc.contributor.authorPons Rodríguez, Anna
dc.contributor.authorForné Izquierdo, Carles
dc.contributor.authorVilaplana Mayoral, Jordi
dc.contributor.authorCruz Esteve, María Inés
dc.contributor.authorSánchez-López, Isabel
dc.contributor.authorReñé Reñé, Mercè
dc.contributor.authorCazorla, Cristina
dc.contributor.authorHernández Andreu, Marta
dc.contributor.authorGalindo Ortego, Gisela
dc.contributor.authorLlorens Gabandé, Montserrat
dc.contributor.authorLaza-Vásquez, Celmira
dc.contributor.authorBalaguer Llaquet, Pau
dc.contributor.authorMartínez Alonso, Montserrat
dc.contributor.authorRué i Monné, Montserrat
dc.description.abstractIntroduction Personalised cancer screening aims to improve benefits, reduce harms and being more cost-effective than age-based screening. The objective of the DECIDO study is to assess the acceptability and feasibility of offering risk-based personalised breast cancer screening and its integration in regular clinical practice in a National Health System setting. Methods and analysis The study is designed as a single-arm proof-of-concept trial. The study sample will include 385 women aged 40-50 years resident in a primary care health area in Spain. The study intervention consists of (1) a baseline visit; (2) breast cancer risk estimation; (3) a second visit for risk communication and screening recommendations based on breast cancer risk and (4) a follow-up to obtain the study outcomes. A polygenic risk score (PRS) will be constructed as a composite likelihood ratio of 83 single nucleotide polymorphisms. The Breast Cancer Surveillance Consortium risk model, including age, race/ethnicity, family history of breast cancer, benign breast disease and breast density will be used to estimate a preliminary 5-year absolute risk of breast cancer. A Bayesian approach will be used to update this risk with the PRS value. The primary outcome measures will be attitude towards, intention to participate in and satisfaction with personalised breast cancer screening. Secondary outcomes will include the proportions of women who accept to participate and who complete the different phases of the study. The exact binomial and the Student's t-test will be used to obtain 95% CIs. Ethics and dissemination The study protocol was approved by the Drug Research Ethics Committee of the University Hospital Arnau de Vilanova. The trial will be conducted in compliance with this study protocol, the Declaration of Helsinki and Good Clinical Practice. The results will be published in peer-reviewed scientific journals and disseminated in scientific conferences and media. Trial registration number NCT03791008.
dc.description.sponsorshipThis study was supported by the research grant 'Personalized breast cancer screening: assessment of its feasibility and acceptability in the National Health System' (PI17/00834) from the Instituto de Salud Carlos III and cofunded by Fondo Europeo de Desarrollo Regional (FEDER) 'Una manera de hacer Europa'. Celmira Laza Vásquez received a grant from Santander Program scholarship 2020 as a predoctoral fellow at the University of Lleida. The non-profit organisation Oncolliga Lleida (grant number N/A) will fund part of the genomic analyses for breast cancer risk assessment.
dc.publisherBMJ Publishing Group
dc.relation.isformatofReproducció del document publicat a:
dc.relation.ispartofBmj Open, 2020, vol. 10, num. 12, p. e044597
dc.rightscc-by-nc (c) Pons Rodríguez, Anna et al., 2020
dc.titleFeasibility and acceptability of personalised breast cancer screening (DECIDO study): protocol of a single-arm proof-of-concept trial

Files in this item


This item appears in the following Collection(s)

Show simple item record

cc-by-nc (c) Pons Rodríguez, Anna et al., 2020
Except where otherwise noted, this item's license is described as cc-by-nc (c) Pons Rodríguez, Anna et al., 2020